Home 2023

Biogen

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly
Bioprocessing

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly

Alex Philippidis -
0
Biogen to Acquire Reata for $7.3B, Adding to Neuro Drug Portfolio
Drug Discovery

Biogen to Acquire Reata for $7.3B, Adding to Neuro Drug Portfolio

Alex Philippidis -
0
StockWatch: Layoffs Extend Biogen’s Stock Skid
Drug Discovery

StockWatch: Layoffs Extend Biogen’s Stock Skid

Alex Philippidis -
0
AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment
Artificial Intelligence

AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment

Alex Philippidis -
22
Beacon of Light: Retinal Gene Therapy Developer Launches with $120M
Drug Discovery

Beacon of Light: Retinal Gene Therapy Developer Launches with $120M

Alex Philippidis -
21
Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
Genome Editing

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

Alex Philippidis -
0
Sangamo Eliminating 27% of U.S. Workforce, Refocusing Pipeline
Drug Discovery

Sangamo Eliminating 27% of U.S. Workforce, Refocusing Pipeline

Alex Philippidis -
0
StockWatch: FDA Panel Enables Accelerated OK for Biogen ALS Drug
News

StockWatch: FDA Panel Enables Accelerated OK for Biogen ALS Drug

Alex Philippidis -
0
The Unbearable Cost of Drug Development: Deloitte Report Shows 15% Jump in R&D to $2.3 Billion
Cancer

The Unbearable Cost of Drug Development: Deloitte Report Shows 15% Jump in R&D to $2.3 Billion

Alex Philippidis -
0
StockWatch: Biogen’s New CEO Takes Slow Approach to New Cost Cuts
Cancer

StockWatch: Biogen’s New CEO Takes Slow Approach to New Cost Cuts

Alex Philippidis -
26
123...20Page 1 of 20
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.